At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 37 enrolled
Drug / intervention
GSK's candidate Mycobacterium tuberculosis vaccine 692342 +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine (692342) in HIV-positive Adults.
In Brief
A Phase 2 clinical trial evaluating GSK's candidate Mycobacterium tuberculosis vaccine 692342, Control vaccine with the adjuvant system., and 1 other intervention for Tuberculosis. Completed, enrolled 37 participants across 1 site.
Detailed Summary
This study will assess the safety and immunogenicity of a GSK Biologicals' candidate TB vaccine (692342) administered at 0, 1 month to HIV-positive adults living in Switzerland.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTuberculosis
CountriesSwitzerland
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2008
First PostedJul 2008
Primary CompletionMay 2009
TodayJul 2026
First PostedJul 1, 2008
Enrollment StartJun 30, 2008
Primary CompletionMay 27, 2009
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 18.0 years ago
Interventions
GSK's candidate Mycobacterium tuberculosis vaccine 692342biological
Intramuscular injection, 2 doses at 0, 1 month
Control vaccine with the adjuvant system.biological
Intramuscular injection, 2 doses at 0, 1 month
Control vaccine with physiological salinebiological
Intramuscular injection, 2 doses at 0, 1 month